SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 4,231.93 |
Enterprise Value ($M) | 4,188.01 |
Book Value ($M) | 327.94 |
Book Value / Share | 5.00 |
Price / Book | 12.90 |
NCAV ($M) | 278.12 |
NCAV / Share | 4.24 |
Price / NCAV | 15.22 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.10 |
Return on Assets (ROA) | -0.12 |
Return on Equity (ROE) | -0.19 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 7.86 |
Current Ratio | 7.86 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 330.03 |
Assets | 379.85 |
Liabilities | 51.91 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 58.88 |
Operating Income | -44.25 |
Net Income | -32.18 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -79.01 |
Cash from Investing | -55.56 |
Cash from Financing | 165.12 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | BlackRock Inc. | 4.60 | -1.05 | |
13G/A | Lynx1 Capital Management LP | 6.60 | 22.00 | |
13G/A | Cormorant Asset Management, LP | 4.39 | -10.53 | |
13G/A | Paradigm Biocapital Advisors LP | 5.50 | 37.07 | |
13G/A | Omega Fund VI, L.P. | 0.00 | -100.00 | |
13G/A | Ra Capital Management, L.p. | 9.99 | 34.24 | |
13G/A | Great Point Partners Llc | 6.37 | 1.81 | |
13D/A | Orbimed Advisors Llc | 4.60 | -36.58 | |
13D/A | Frazier Life Sciences VIII, L.P. | 9.80 | 92.25 | |
13D/A | Decheng Capital China Life Sciences USD Fund III, L.P. | 14.10 | 4.85 | |
13D/A | Alpine ImmunoSciences, L.P. | 7.20 | 9.23 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
93,589 | 1,074,651 | 8.71 | |
801,559 | 2,936,111 | 27.30 | |
173,683 | 1,660,633 | 10.46 | |
779,677 | 889,129 | 87.69 | |
(click for more detail) |
Similar Companies | |
---|---|
ACRV – Acrivon Therapeutics, Inc. | ADMA – ADMA Biologics, Inc. |
ALIM – Alimera Sciences, Inc. | ALT – Altimmune, Inc. |
ANIP – ANI Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io